chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Really bad body aches; Shivering from cold chills; Fatigue and less energy; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Really bad body aches), NASOPHARYNGITIS (Shivering from cold chills) and FATIGUE (Fatigue and less energy) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 23-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, the patient experienced PAIN (Really bad body aches), NASOPHARYNGITIS (Shivering from cold chills) and FATIGUE (Fatigue and less energy). At the time of the report, PAIN (Really bad body aches), NASOPHARYNGITIS (Shivering from cold chills) and FATIGUE (Fatigue and less energy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. Treatment information was not reported.
Subq area of rt arm red, itchy, swollen, and warm to touch.  Reaction started 11 hrs after vaccine given.  Father stated he had given pt   one ibuprofen tablet and some benadryl  on 7/31/2019.  Parent was advised by FNP to continue with ibuprofen and benadryl and to use cold compresses and to seek medical attention of mouth/throat swelling occurs or if pt has reaction in other areas of body.
Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Severe, Systemic: Fainting / Unresponsive-Severe, Systemic: Flushed / Sweating-Severe, Systemic: Nausea-Severe, Systemic: Shakiness-Severe, Systemic: Vomiting-Severe, Systemic: Weakness-Severe, Additional Details: Patient approached pharmacy and appeared normal/healthy. Vaccine was mixed/prepared/given proper protocol. Patient sat down after vaccination and within 5-10 minutes he fainted face forward from a seated position. He regained consciousness within 30 seconds of fainting. He then vomited within minutes after he sat up after fainting. A nurse practitioner was in store shopping and stopped by to read his blood pressure (135/76) then the EMT arrived within a minute of the blood pressure reading.
Pt complained of tiredness, peripheral vision loss, and hazy peripheral vision shortly after receiving influenza vaccination at a flu shot clinic held at hospital provided by pharmacists from Drug Store. She is an employee of the hospital and was monitored by medical personell until symptom resolution around 6:00. She denied being treated at the emergency room. Vitals and blood glucose remained normal and no other symptoms occurred.
She received her shot in her left deltoid, but reported a tingling sensation down her right arm beginning at her right shoulder and going down to her right hand.
drastic deteriation of eye sight; extreme chest pain; extreme lungs pain; hard to breathe; loss of appetite; feeling of numbness in limbs; extreme anxiety; insomnia; dizziness; mild headaches; mild chills; mild brain fog; stiff neck; stiff  jaws; feeling hyper activated; This is a spontaneous report from a contactable other hcp (patient) reported for herself that . A 57-years-old non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Batch/Lot Number: EL9266), dose 2 via an unspecified route of administration, administered in Arm Left on 14Feb2021 (Age at vaccination 57-years-old) as DOSE 2, SINGLE for covid-19 immunization.  Medical history included mitral valve prolapse, anxiety, presyncope from an unknown date and unknown if ongoing. Patient had no known allergy. Concomitant medications included estradiol (VIVELLE DOT), estradiol (ESTRACE) taken for an unspecified indication, start and stop date were not reported. Patient previously took first dose of BNT162B2 (Lot number=EL9262), in Arm Left, on 25Jan2021 at 08:15 (Age at vaccination 57-years-old), for COVID-19 immunization. Patient did not receive other vaccine in four weeks of vaccination. Patient was not diagnosed with COVID-19, prior vaccination. Patient has been tested for COVID-19, post vaccination. On 16Feb2021 the patient experienced drastic deteriation of eyesight, extreme chest/lungs pain, hard to breathe, loss of appetite, feeling of numbness in limbs, extreme anxiety, insomnia, dizziness, for 10 days of second dose of vaccine. its almost one month, I am still experiencing, extreme anxiety, mild headaches, odd mild chills, mild brain fog, numbness in limbs, stiff neck, jaws, feeling hyper activated. The adverse events resulted in Doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 04Mar2021. No treatment received for adverse events. Outcome of the events was not recovered,  No follow-up attempts are possible. No further information is expected.
This spontaneous report was received from a medical assistant concerning an approximately 8 week old male patient with no pertinent medical history. On 12-MAR-2013, the patient was vaccinated with the first dose of Liquid PEDVAXHIB (lot number and expiry date reported as 0419AE and 17-AUG-2014 respectively, dose and route unspecified). No concomitant medications were reported. On 12-MAR-2013, the patient developed an injection site reaction which included swelling, redness and a knot at the injection site. On an unknown date, the patient sought an unspecified medical attention. On an unknown date, the patient had recovered from an injection site reaction which included swelling, redness and a knot at the injection site. The relatedness for an injection site reaction which included swelling, redness and a knot at the injection site was unknown for Liquid PEDVAXHIB. Additional information has been requested.
Memory loss. Will wake up in morning and not know where she is. Will be talking and wrong words come out. Will be driving somewhere and won't know where she's going. 8/4/08-GYN notes received from DOS 10/24/07-7/17/08-chlamdyia infection. Patient feels she has issues with blood sugar will see PCP 9/11/08-records received-office visit 5/4/07-C/O exercise induced asthma. Office visit 5/10/07-C/O acute right knee pain. 7/11/07-office visit follow up for asthma, 8/30/07-GI complaints vomiting and diarrhea.10/9/07-C/O left hip pain for a few months. Lump above left hip present for some time. 2/13/08-Acute upper respiratory infection. 7/21/08-stress reaction in proximal tibial knee possible osteomalacia.7/24/08-difficulty with memory for about 1 year, trouble finding work, slurred speech once happening more frequently.
Soreness and Numbness starting approx 2:30 pm at injection site and continuing to full arm. Still un-comfortable the next morning.
Pt. was given Pfizer Monovalent for children under the age of 5 instead of the appropriate vaccine for his age group.   Pediatrician aware. and confirmced that pt. will be eligible to receive the Pfizer Bivalent vaccine for children from ages 5 to 11 two months following his recent vaccine.
Information has been received from a Licensed Vocational Nurse referring to multiple unspecified patients of unknown age and gender. On unknown dates, the patients were vaccinated with improperly stored RECOMBIVAX HB, lot # K016005, expiration date 27-AUG-2016 (dose and route of administration were not reported). No adverse effects were reported. Follow up information has been received from the Licensed Practical Nurse (initial reported as Licensed Vocational Nurse) during a telephone call on 13-NOV-2015 concerning one of the multiple patients of unknown age and gender. On 03-AUG-2015, the patient vaccinated with the improperly stored RECOMBIVAX HB. Additional information has been requested. Patient's information, products, events and narrative were updated.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 06-SEP-2016, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 13-SEP-2016, the patient was treated at a medical center/hospital (by an unspecified healthcare professional) for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX, and/or despite receiving ZOSTAVAX for long term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Patient received a 3rd dose of Moderna monovalent instead of the 1st dose of Moderna bivalent booster. Patient was contacted and given the option of either retake the correct booster dose and be reevaluated by the provider, or not retake it.
Patient developed nausea/vomiting, epigastric pain, chills, mylagias about 12hr after vaccine admin.  Seen  in ED about 24hr after vaccine admin, found to have acute pancreatitis without alternative etiology.  Labs and symptoms resolved within 24hr with conservative care. No other complications.
PATIENT RECEIVED  UN-DILUTED PFIZER VACCINE EXHIBITED FEVER 101, ACHY AND FATUGUED
left arm pain, fatigue, fever, but 4 days after vaccination felt a hot sensation left side of head/ as if heat coming out of ear.  developed elevated BP approx 1 week after vaccination, then ongoing HTN needing medication. ongoing left arm, left leg, left side of neck, left side of head pain. re-exam 9/22/2021: left UE weakness: 4/5 hand grip/shoulder abduction, hip flexion, knee extension, resisted lateral rotation of head to the left, decreased sensation left side of face, left arm, left leg- weakness and numbness all on left side diffusely.
Fevers of 104 degrees Fahrenheit onset 1/11/14. Lasted 3 days. Swollen lymph nodes behind left ear. Twitching jerking motions in sleep. Irritability for 1 week. Raised rash onset tue. Resolved on Thursday with low grade fever. On 1/20/14. Red rash on trunk and back, neck. Appears like a measles rash.
Difficulty in breathing; Rash all over her body; Anaphylactic reaction; A spontaneous report  was received from a pharmacist for a 47-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced anaphylactic reaction, rash all over her body and difficulty in breathing.  The patient's medical history was not provided. No concomitant product use was reported.  On 15 Feb 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: not provided) intramuscularly for prophylaxis of COVID-19 infection.   On 24 Feb 2021, 10 days after vaccination the patient experienced an anaphylactic reaction. The patient had severe itching on her palm and knee which later turn into rash. The patient also had swelling of her lips and face. The patient went to the emergency room where she got prednisone 50mg for 3 days.  On 26 Feb 2021, the patient got rash all over her body and difficulty in breathing. The patient went again to the emergency room.   Treatment information included prednisone 50mg for 3 days.  Action taken with mRNA-1273 was unknown.  The outcome of the event, anaphylactic reaction was not recovered/ not resolved and the outcome for events rash all over her body and difficulty in breathing was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
Patient woke vomiting and refusing formula on 7/14/19. Mom took to ER and they done abdominal ultrasound. Findings of ileocolic intussusception were found. Patient was admitted for observation for 2 days after a reduction of intussusception.
Patient reported diarrhea.  Subsequently diagnosed with lymphocytic colitis by colonscopy March 21, 2022
Patient presents with redness and warmth at site of zoster vaccination recieved 06/25/09.
Assessment/Plan:  1. RASH  2. ADVERSE EFFECT OF CORONAVIRUS COVID-19 VACCINE, INIT  Doesn't seem cellulitis in nature.  Non descriptive - post inflammatory response. Trial of steroids recommended.  Recommended to report to VAERS.   Orders Placed This Encounter ?Triamcinolone Acetonide (ARISTOCORT/KENALOG) 0.025 % Top Oint
A report was received from a health care professional on 22OCT2003 concerning a 2 year old male vaccinee who inadvertently received Fluvirin on 21OCT2003. On 21OCT2003 the 2 year old vaccinee received Fluvirin . The vaccinee did not exhibit any adverse reaction as a result. There was insufficient information to determine the reporter's causality assessment. Update 1 12NOV2003: follow up information received from a health care professional indicated that the vaccinee experienced no adverse reaction.
Diagnosis of myasthenia gravis after symptoms of dry eyes and eye lid drooping and inability to open eyes.
Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022; Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022) and PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     It was unknown if patient had any acute illnesses at the time of vaccination and up to one month before. It was unknown if the patient had chronic or long-standing health conditions.     On 27-Jan-2022 at 12:01 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Jan-2022 at 12:01 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022) and PRODUCT STORAGE ERROR (Vaccines went into 2-8 C thaw state on or about 24-Dec-2021 and administered on 27-Jan-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported.  It was unknown if any prescriptions, over-the-counter-medications, dietary supplements, or herbal remedies were being taken by the patient at the time of vaccination and/or at the time of the adverse event.  It was unknown if other vaccines were given on the same day or within one month prior to any dose of Moderna COVID-19 Vaccine to the patient.  The patient received vaccine past its 30 day expiry date The vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021. The vaccine was administered up until it manufactured expiry date of 04-Apr-2022. The patient received booster dose.  No treatment information was provided.
This spontaneous report as received from a registered nurse refers to a patient of unknown demographics. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapy were not reported. On 25-JUL-2018, the patient was vaccinated with improperly stored doses of PROQUAD either from lot # R002939, expiry date: 29-JUL-2019 or lot # R006218, expiry date: 28-AUG-2019 (dose, frequency and route were not reported) for prophylaxis. Sterile diluent (MRK INJ) was properly stored. No adverse effects were reported. No product quality complaint was involved. The PROQUAD was stored in temperature of 15 degree Fahrenheit (F) to 46 F for 14 hours on 16-JUN-2018. No previous temperature excursion was reported. A digital data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1808USA001261: US-009507513-1808USA004381:Original Case : 1808USA001261; US-009507513-1808USA004382:Original Case : 1808USA001261; US-009507513-1808USA004383:Original Case : 1808USA001261; US-009507513-1808USA004384:Original Case : 1808USA001261; US-009507513-1808USA004385:Original Case : 1808USA001261; US-009507513-1808USA004380:Original Case : 1808USA001261; US-009507513-1808USA004379:Original Case : 1808USA001261; US-009507513-1808USA004376:Original Case : 1808USA001261; US-009507513-1808USA004377:Original Case : 1808USA001261; US-009507513-1808USA004378:Original Case : 1808USA001261; US-009507513-1808USA004386:Original Case : 1808USA001261; US-009507513-1808USA004387:Original Case : 1808USA001261; US-009507513-1808USA004388:Original Case : 1808USA001261; US-009507513-1808USA004362:Original Case : 1808USA001261; US-009507513-1808USA004363:Original Case : 1808USA001261; US-009507513-1808USA004389:Original Case : 1808USA001261; US-009507513-1808USA004390:Original Case : 1808USA001261; US-009507513-1808USA004391:Original Case : 1808USA001261; US-009507513-1808USA004364:Original Case : 1808USA001261; US-009507513-1808USA004392:Original Case : 1808USA001261; US-009507513-1808USA004393:Original Case : 1808USA001261; US-009507513-1808USA004395:Original Case : 1808USA001261; US-009507513-1808USA004396:Original Case : 1808USA001261; US-009507513-1808USA004365:Original Case : 1808USA001261; US-009507513-1808USA004366:Original Case : 1808USA001261; US-009507513-1808USA004367:Original Case : 1808USA001261; US-009507513-1808USA004397:Original Case : 1808USA001261; US-009507513-1808USA004398:Original Case : 1808USA001261; US-009507513-1808USA004399:Original Case : 1808USA001261; US-009507513-1808USA004368:Original Case : 1808USA001261; US-009507513-1808USA004369:Original Case : 1808USA001261; US-009507513-1808USA004400:Original Case : 1808USA001261; US-009507513-1808USA004401:Original Case : 1808USA001261; US-009507513-1808USA004370:Original Case : 1808USA00126.
pt recv vax & devel a fever of 104 & was given APAP & put in bath tube w/cool water;All this was not working to reduce fever;pt had sz & convuls;amb was called;
Fever to 101.5 day following vaccination, Large area redness induration heat , 9-10 diameter about injection site,  1 cm area central vesicles water filled 48 hrs later
skin rash; This spontaneous case was reported by a nurse and describes the occurrence of RASH (skin rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (skin rash). At the time of the report, RASH (skin rash) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product information was reported.   Treatment information include some type of topical steroid cream.   This case was linked to US-MODERNATX, INC.-MOD-2021-027273 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-027273:Group reporting
nausea - from 0400 2/4 until 1600 2/4 vomiting x1 episode 2/4 at 0830 myalgias, fatigue, fever and chills from 0400 2/4 until 2/6 pounding headache all day 2/4 and 2/5
Days 1-4 - enlarged, red, hot welt at injection site size of palm, tender to touch. Complete recovery with no medications.   Day 10 - started with itchy upper arm and ended the day with the welt at the injection site returning - itchy, hives, lump and hot to the touch.   Photos available
Early in the morning I started developing a headache.  I typically have migraines and thought this was just what I was getting.  I took Excedrin Migraine to try to keep it from getting worse, but it continued to get worse and worse and worse.  About noon I found that I could not stand any light or sound - this is not typical for me as I can usually listen to things during a headache even if I can't open my eyes.  I ended up spending all the rest of the day and the night alone in a dark noiseless room.  I told my husband it was the worse headache I had ever had.  It was only later that we found out the shot caused blood clots in the head.  I did not correlate the two because it had been so long - almost 3 weeks - since my vaccination.
Red rash all over face, head, ears, neck; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of RASH ERYTHEMATOUS (Red rash all over face, head, ears, neck) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017B21A and 048B21A) for COVID-19 vaccination.     The patient's past medical history included Autoimmune arthritis.   On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Apr-2021, the patient experienced RASH ERYTHEMATOUS (Red rash all over face, head, ears, neck) (seriousness criteria disability and medically significant). The patient was treated with TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE [TRIAMCINOLONE ACETONIDE]) for Rash, at an unspecified dose and frequency. At the time of the report, RASH ERYTHEMATOUS (Red rash all over face, head, ears, neck) had not resolved.            Concomitant products were not provided/unknown.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.   This case was linked to MOD-2021-194729 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Jun-2021: Follow-up received on 02-Jun-2021 contains non-significant information: E-mail id added; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.